|
2,120
|
| 17352 |
LasR/I-3OC12-(HSL)-system
|
|
increases_expression of
|
lasB
|
in P.aeruginosa
|
|
10922036
|
Pseudomonas aeruginosa diseases
|
|
2,123
|
| 17682 |
lasB
|
|
decreases_activity of
|
establishment of skin barrier
|
|
| 17684 |
lasB
|
|
decreases_quantity of
|
SFTPA1
|
|
| 17685 |
lasB
|
|
decreases_quantity of
|
SFTPD
|
|
|
15695491
|
Pseudomonas aeruginosa diseases
|
|
2,285
|
| 19513 |
lasR
|
|
increases_quantity of
|
lasB
|
|
| 19517 |
rhlR
|
|
increases_quantity of
|
lasB
|
|
| 19572 |
2-Heptyl-3-hydroxy-4-quinolone, PQS
|
|
increases_expression of
|
lasB
|
|
| 19573 |
N-Butyryl-HSL
|
|
increases_expression of
|
lasB
|
|
|
20738404
|
Pseudomonas aeruginosa diseases
|
|
2,464
|
| 22943 |
T2SS (Xcp)
|
|
increases_transport of
|
lasB
|
into the extracellular medium
|
|
20947426
|
Pseudomonas aeruginosa diseases
|
|
2,507
|
| 23348 |
lasB
|
|
decreases_quantity of
|
SFTPA1
|
|
| 23349 |
lasB
|
|
decreases_quantity of
|
SFTPD
|
|
| 23350 |
lasB
|
|
decreases_activity of
|
F2RL1
|
|
|
16427231
|
Pseudomonas aeruginosa diseases
|
|
2,541
|
| 23649 |
P. aeruginosa infection, chronic
|
|
increases_quantity of
|
lasB
|
in sera of CF patients (from stationary-phase cultures)
|
| 23653 |
Acyl-HSL quorum sensing
|
|
affects_quantity of
|
lasB
|
in sera of CF patients (from stationary-phase cultures)
|
|
18663005
|
Pseudomonas aeruginosa diseases
|
|
2,781
|
| 25714 |
lasB
|
|
decreases_quantity of
|
ELN
|
|
| 33889 |
P. aeruginosa infection, acute
|
|
increases_activity of
|
lasB
|
|
| 40199 |
lasB
|
|
increases_activity of
|
lung hemorrhage
|
|
|
21184216
|
Pseudomonas aeruginosa diseases
|
|
2,783
|
| 25722 |
desB
|
|
affects_activity of
|
lasB
|
|
|
21184216
|
Pseudomonas aeruginosa diseases
|
|
2,853
|
| 26294 |
kinB
|
|
increases_quantity of
|
lasB
|
in a manner independent of AlgB
|
|
21515773
|
Pseudomonas aeruginosa diseases
|
|
2,953
|
| 26937 |
xcpP
|
|
interacts (colocalizes) with
|
lasB
|
experiments performed with the periplasmic soluble domains
|
| 26943 |
xcpQ
|
|
interacts (colocalizes) with
|
lasB
|
experiments performed with the periplasmic soluble domains
|
| 26946 |
lasB
|
|
interacts (colocalizes) with
|
xcpU
|
experiments performed with the periplasmic soluble domains
|
| 26948 |
lasB
|
|
interacts (colocalizes) with
|
xcpV
|
experiments performed with the periplasmic soluble domains
|
| 26949 |
lasB
|
|
interacts (colocalizes) with
|
xcpX
|
experiments performed with the periplasmic soluble domains
|
|
21949187
|
Pseudomonas aeruginosa diseases
|
|
3,113
|
| 28612 |
flagellum
|
NOT |
affects transport of
|
lasB
|
|
|
17307856
|
Pseudomonas aeruginosa diseases
|
|
3,115
|
| 28631 |
qteE
|
|
affects_expression of
|
lasB
|
|
| 28635 |
qteE
|
|
affects_quantity of
|
lasB
|
|
|
20378835
|
Pseudomonas aeruginosa diseases
|
|
3,130
|
| 28810 |
lasB
|
|
is localized in
|
bacterial membrane vesicle, MV
|
|
|
22103313
|
Pseudomonas aeruginosa diseases
|
|
3,156
|
| 29043 |
oprF
|
|
increases_quantity of
|
lasB
|
during the entry into the stationary phase
|
|
21189321
|
Pseudomonas aeruginosa diseases
|
|
3,584
|
| 33538 |
lasB
|
|
increases_activity of
|
bacterial-type flagellum-dependent swarming motility
|
|
| 33547 |
lasB
|
|
increases_activity of
|
biofilm formation
|
|
|
18245294
|
Pseudomonas aeruginosa diseases
|
|
3,683
|
| 35362 |
phoQ
|
|
increases_expression of
|
lasB
|
during adherence to HBE cells
|
|
22710876
|
Pseudomonas aeruginosa diseases
|
|
3,855
|
| 38724 |
lasB
|
|
increases_activity of
|
immune evasion
|
|
| 38725 |
lasB
|
|
decreases_activity of
|
complement component C3b binding
|
|
|
17709513
|
Pseudomonas aeruginosa diseases
|
|
3,900
|
| 39552 |
N-Acetyl-D-glucosamine
|
|
increases_quantity of
|
lasB
|
in P. aeruginosa
|
| 39553 |
peptidoglycan, exogenous
|
|
increases_quantity of
|
lasB
|
in P. aeruginosa
|
|
23277552
|
Pseudomonas aeruginosa diseases
|
|
3,902
|
| 39599 |
N-Acetyl-D-glucosamine
|
|
increases_expression of
|
lasB
|
in P. aeruginosa, grown with GlcNAc as the primary carbon and energy source
|
|
21169497
|
Pseudomonas aeruginosa diseases
|
|
3,959
|
| 40193 |
T2SS (hybrid-Xcp)
|
|
increases_transport of
|
lasB
|
|
|
17351035
|
Pseudomonas aeruginosa diseases
|
|
3,961
|
| 40261 |
nitrate reductase complex, narGHI
|
|
increases_transport of
|
lasB
|
|
| 40263 |
nirS
|
|
increases_transport of
|
lasB
|
|
|
19651860
|
Pseudomonas aeruginosa diseases
|
|
4,202
|
| 43125 |
PA3699
|
|
decreases_quantity of
|
lasB
|
|
|
23861975
|
Pseudomonas aeruginosa diseases
|
|
4,642
|
| 46235 |
dsbA1
|
|
affects_folding of
|
lasB
|
|
| 46308 |
dsbA1
|
|
increases_transport of
|
lasB
|
|
|
24327342
|
Pseudomonas aeruginosa diseases
|
|
4,659
|
| 46380 |
CAMP
|
|
increases_quantity of
|
lasB
|
physiological concentrations of LL-37
|
|
24349231
|
Pseudomonas aeruginosa diseases
|
|
4,941
|
| 48845 |
lasB
|
|
decreases_quantity of
|
CDH5
|
in infected HUVEC cells
|
| 48848 |
lasB
|
NOT |
decreases_quantity of
|
CDH1
|
in epithelial cells
|
|
24626230
|
Pseudomonas aeruginosa diseases
|
|
4,942
|
| 48847 |
lasB
|
|
decreases_quantity of
|
CDH5
|
in a mouse model of acute pneumonia
|
|
24626230
|
Pseudomonas aeruginosa diseases
|
|
5,271
|
| 51520 |
T2SS (Txc)
|
|
increases_transport of
|
lasB
|
|
|
24748613
|
Pseudomonas aeruginosa diseases
|
|
6,463
|
| 61849 |
morA
|
|
decreases_quantity of
|
lasB
|
|
| 61882 |
morA
|
|
decreases_activity of
|
lasB
|
|
|
25894344
|
Pseudomonas aeruginosa diseases
|
|
6,554
|
| 62284 |
lasB
|
|
increases_activity of
|
ERK1 and ERK2 cascade
|
|
| 62291 |
lasB
|
|
increases_activity of
|
MAPK1
|
|
| 62292 |
lasB
|
|
increases_phosphorylation of
|
MAPK3
|
|
| 62293 |
lasB
|
|
increases_phosphorylation of
|
MAPK1
|
|
| 62294 |
lasB
|
|
increases_activity of
|
EGFR
|
|
| 62295 |
lasB
|
|
increases_expression of
|
CXCL8
|
|
| 62296 |
lasB
|
|
increases_quantity of
|
CXCL8
|
|
| 62297 |
lasB
|
|
increases_activity of
|
I-kappaB kinase/NF-kappaB signaling
|
|
| 62299 |
lasB
|
|
increases_activity of
|
MAPK3
|
|
|
24385476
|
Pseudomonas aeruginosa diseases
|
HoPaCI